Alnylam announces interim phase 1 data of nucresiran (aln-ttrsc04) showing rapid knockdown of ttr that is sustained at six months following a single dose

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the presentation of new results from its phase 1 study of nucresiran (formerly aln-ttrsc04), a next-generation rnai therapeutic in development for the treatment of transthyretin (attr) amyloidosis. the data were presented in an oral session at the american heart association scientific sessions 2024 in chicago. these new results demonstrated that a single dose o.
ALNY Ratings Summary
ALNY Quant Ranking